Zoetis Inc

ZTS

127.420USD

+0.715+0.56%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Zoetis Inc's Score

Industry at a Glance

Industry Ranking

27 / 159

Overall Ranking

78 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Zoetis Inc Highlights

StrengthsRisks

Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 9.26B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 32.66%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 32.66%.

Undervalued

The company’s latest PE is 21.45, at a low 3-year percentile range.

Held by Mairs and Power

Star Investor Mairs and Power holds 7.22K shares of this stock.

Analyst Rating

Based on 20 analysts

Buy

Current Rating

156.334

Target Price

+23.39%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Zoetis Inc is 8.99, ranking 22 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 2.40B, representing a year-over-year increase of 0.50%, while its net profit experienced a year-over-year increase of 5.72%.

Score

Industry at a Glance

Previous score

8.99

Change

0



Financials

6.88

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.72

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

9.37

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Zoetis Inc is 5.60, ranking 145 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 21.45, which is 95.55% below the recent high of 41.95 and 9.16% above the recent low of 19.49.

Score

Industry at a Glance

Previous score

5.60

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 27/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Zoetis Inc is 7.80, ranking 95 out of 159 in the Pharmaceuticals industry. The average price target is 165.00, with a high of 200.00 and a low of 130.00.

Score

Industry at a Glance

Previous score

7.80

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Zoetis Inc is 8.77, ranking 49 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 131.56 and the support level at 121.67, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.78

Change

-0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Zoetis Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 99.51%, representing a quarter-over-quarter increase of 0.40%. The largest institutional shareholder is The Vanguard, holding a total of 47.57M shares, representing 10.79% of shares outstanding, with 16.20% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

47.78M

+13.48%

BlackRock Institutional Trust Company, N.A.

22.80M

+0.64%

State Street Investment Management (US)

19.65M

-0.46%

State Farm Insurance Companies

16.87M

+0.13%

Geode Capital Management, L.L.C.

11.14M

+0.52%

Wellington Management Company, LLP

8.54M

-3.92%

Polen Capital Management, LLC

7.52M

-10.74%

Morgan Stanley Investment Management Ltd. (UK)

7.48M

+10.69%

Wells Fargo Advisors

5.64M

-3.32%

Norges Bank Investment Management (NBIM)

5.19M

+2.60%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Zoetis Inc is 7.34, ranking 37 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.96. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Zoetis Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Zoetis Inc

ZTS

8.14 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

9.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Regeneron Pharmaceuticals Inc

REGN

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment